Annovis Bio, Inc. announced successful completion of data cleaning for its Phase III study of buntanetap in patients with early Parkinson?s disease (PD). Topline efficacy data is expected in June. The Phase III study was completed in Fourth Quarter 2023 with an original plan for data announcement in First Quarter 2024, however the Company faced a delay in the process of data cleaning beyond the original prognosis.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.29 USD | +2.97% | -12.27% | -61.02% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-61.02% | 81.44M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- ANVS Stock
- News Annovis Bio, Inc.
- Annovis Bio, Inc. Announces Unblinding of the Buntanetap Phase III Data in Parkinson?s Disease